Possible Role of the Transglutaminases in the Pathogenesis of Alzheimer's Disease and Other Neurodegenerative Diseases
Author(s) -
Antonio M. Martin,
Giulia De Vivo,
Vittorio Gentile
Publication year - 2011
Publication title -
international journal of alzheimer s disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.657
H-Index - 49
eISSN - 2090-8024
pISSN - 2090-0252
DOI - 10.4061/2011/865432
Subject(s) - tissue transglutaminase , pathogenesis , progressive supranuclear palsy , disease , neurodegeneration , alzheimer's disease , medicine , degenerative disease , biology , neuroscience , enzyme , immunology , biochemistry , pathology
Transglutaminases are ubiquitous enzymes which catalyze posttranslational modifications of proteins. Recently, transglutaminase-catalyzed post-translational modification of proteins has been shown to be involved in the molecular mechanisms responsible for human diseases. Transglutaminase activity has been hypothesized to be involved also in the pathogenetic mechanisms responsible for several human neurodegenerative diseases. Alzheimer's disease and other neurodegenerative diseases, such as Parkinson's disease, supranuclear palsy, Huntington's disease, and other polyglutamine diseases, are characterized in part by aberrant cerebral transglutaminase activity and by increased cross-linked proteins in affected brains. This paper focuses on the possible molecular mechanisms by which transglutaminase activity could be involved in the pathogenesis of Alzheimer's disease and other neurodegenerative diseases, and on the possible therapeutic effects of selective transglutaminase inhibitors for the cure of patients with diseases characterized by aberrant transglutaminase activity
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom